What is the role of pazopanib in the treatment of ovarian cancer?

Updated: Aug 10, 2020
  • Author: Andrew E Green, MD; Chief Editor: Yukio Sonoda, MD  more...
  • Print

Adding pazopanib, a kinase inhibitor, to the standard postsurgical chemotherapy regimen has shown promise for progression-free survival in advanced ovarian cancer. In a study of 940 women with advanced ovarian cancer (epithelial ovarian, fallopian tube, or primary peritoneal cancers) who had not shown evidence of postsurgical progression after five or more cycles of platinum-taxane chemotherapy, progression-free survival in these patients was increased with the addition of pazopanib to standard treatment. [71]

Most of the women in the study had stage III/IV disease (91%) at initial diagnosis and no residual disease after surgery (58%). [71] At a median follow-up of 24 months, patients treated with 800 mg of pazopanib once daily had a prolonged progression-free survival, as compared with those receiving placebo. However, the pazopanib group also had a higher incidence of adverse events and serious adverse events, of which the most common were hypertension, diarrhea, nausea, headache, fatigue, and neutropenia. [71] Four fatal adverse events occurred, three in the pazopanib group and one in the placebo group.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!